Innovative Approaches for Monitoring Cardiotoxicity 2011

EARLY IN VITRO MODELS AND MARKERS
FOR CARDIAC SAFETY PREDICTIONS

Expanding in vitro Biochemical and Cellular Models for Earlier Drug Safety Assessment
Mary Ellen Cvijic, Ph.D., Principal Scientist, Lead Evaluation, Applied Biotechnology, Bristol-Myers Squibb Co.
Development of Translatable Biomarkers for Cardiovascular Safety
Jennifer Colangelo, Ph.D., Associate Director, Drug Safety R&D, Pfizer Global Research and Development
Talk Title to be Announced
Craig T. January, M.D., Ph.D., Professor, Medicine and Physiology, Division of Cardiovascular Medicine, University of Wisconsin-Madison
Biologicals and Cardiac Toxicity Risk
Noël Dybdal, Ph.D., D.V.M., Associate Director, Principal Scientist, Safety Assessment, Genentech, Inc.
Pre-Clinical Strategies for De-Risking the Potential of Cardiovascular Toxicity
Peter Hoffmann, M.D., Ph.D., Executive Director, Pre-Clinical Safety, Novartis Institutes for BioMedical Research

CORRELATING IN VITRO AND IN VIVO DATA

FEATURED PRESENTATION:
Pre-Clinical Strategies for Predicting and Preventing Cardiotoxicity

Thomas Force, M.D., Professor of Medicine & Clinical Director, Center for Translational Medicine, Thomas Jefferson University
Cardiotoxicity: The Pharmaceutical Researcher’s Medusa
Vivek Kadambi, Ph.D., Senior Director, Drug Safety Evaluation, Millennium, The Takeda Oncology Company
Does it Help or Hurt to Know Cardiovascular Biology?
Douglas B. Sawyer, M.D., Ph.D., Lisa M. Jacobson Professor of Medicine and Chief, Cardiovascular Division, Vanderbilt University Medical Center
You Don’t Give Drugs to Normal People, So Why Search for Toxicity in Normal Animals?
Robert Hamlin, Ph.D., Professor, Veterinary Biosciences, Ohio State University
Evolving Trends in Pre-Clinical Cardiac Safety
Gary Gintant, Ph.D., Senior Group Leader, Integrative Pharmacology, Global Pharmaceutical Research & Development, Abbott Laboratories